Wednesday, January 22, 2025
spot_img

Spineway : 2024 revenue of €12 million – 14% growth compared with 2023


Press release        

Ecully, January 22, 2025 – 6.30 p.m.

 

SPINEWAY

2024 revenue of €12 million
14% growth compared with 2023

In thousands of euros 2024 2023 Change

as a %

H1 revenue 6,535 5,431 +20%
H2 revenue 5,415 5,088 +6%
Full-year revenue 11,950 10,519 +14%

Unaudited consolidated data

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, is reporting annual revenue of €11.9 million in FY 2024, representing organic growth of 14% (excluding changes in the scope of consolidation) compared with FY 2023. This acceleration benefited from the successful integration of the Distimp and Spine Innovations acquisitions, which have strengthened the Group’s premium ranges and boosted sales in this segment.

Latin America and Asia were the drivers of overall annual growth, thanks to the introduction of these premium and innovative products to the Group’s long-standing distributors. Continued sales growth in these regions in the fourth quarter enabled the Group to achieve annual revenue of €3.1 million in Latin America (+35% compared with 2023) and €1.9 million in Asia (+12%). In Europe, after a fourth quarter affected by the delayed launch of new ranges, full-year revenue was up 2.5% year on year at €5.3 million. This growth demonstrates the good positioning of Spineway’s products in this demanding and mature market, despite competition exacerbated by stagnant economies and restrictive fiscal policies.

Revenue growth combined with the full impact of cost-cutting measures should help improve the Group’s operating performance1 in fiscal 2024.   Based on the positive trend in its business, Spineway confirms its aim of becoming a major player in less invasive spine treatments.

Next event:
March 24, 2025 – Annual results for 2024

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and more than 70% of its revenue comes from exports.
ISIN: FR001400BVK2 – ALSPW        

Contacts:

SPINEWAY

Shareholder-services line

Available Tuesday through Thursday

+33 (0)806 706 060

  AELIUM

Investor relations

Solène Kennis

[email protected]

 

1 In terms of EBITDA and operating income

Attachment

  • CP_SPW-CA2024_VDEF_EN

Powered by SlickText.com

Hot this week

Interparfums, Inc. Reports Record 2024 Fourth Quarter and Full Year Net Sales

Achieves FY2024 Net Sales of $1.45 Billion2024 Fourth Quarter&...

CPS Announces $442.4 Million Senior Subordinate Asset-Backed Securitization

LAS VEGAS, Nevada, Jan. 22, 2025 (GLOBE...

TowneBank Reports Full Year and Fourth Quarter Financial Results for 2024

SUFFOLK, Va., Jan. 22, 2025 (GLOBE NEWSWIRE)...

Live Oak Bancshares, Inc. Reports Fourth Quarter 2024 Results

WILMINGTON, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE)...

Topics

spot_img

Related Articles

Popular Categories

spot_img